Showing results (71-80 of 95) with videos related to
Sort By:
Pageof 10
The American Journal of Pathology|February 14, 2016
Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in PilomatricomaTakamichi Ito, Gaku Tsuji, Fumitaka Ohno, et al.Journal of Dermatological Science|April 24, 2019
Cyto/chemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenonKazuhisa Furue, Takamichi Ito, Yuka Tanaka, et al.International Journal of Molecular Sciences|April 12, 2022
Role of ERK Pathway in the Pathogenesis of Atopic Dermatitis and Its Potential as a Therapeutic TargetNahoko Zeze, Makiko Kido-Nakahara, Gaku Tsuji, et al.International Journal of Molecular Sciences|January 16, 2020
The EGFR-ERK/JNK-CCL20 Pathway in Scratched Keratinocytes May Underpin Koebnerization in Psoriasis PatientsKazuhisa Furue, Takamichi Ito, Yuka Tanaka, et al.Journal of Clinical Medicine|March 28, 2020
Aryl Hydrocarbon Receptor Activation Downregulates IL-33 Expression in Keratinocytes via Ovo-Like 1Gaku Tsuji, Akiko Hashimoto-Hachiya, Vu Hai Yen, et al.Cell Death & Disease|July 14, 2017
Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitisGaku Tsuji, Akiko Hashimoto-Hachiya, Mari Kiyomatsu-Oda, et al.Journal of Medicinal Food|June 11, 2015
Antioxidant Opuntia ficus-indica Extract Activates AHR-NRF2 Signaling and Upregulates Filaggrin and Loricrin Expression in Human KeratinocytesTakeshi Nakahara, Chikage Mitoma, Akiko Hashimoto-Hachiya, et al.American Journal of Infection Control|January 19, 2016
Risk factors for nosocomial tuberculosis transmission among health care workersYutaka Ito, Miki Nagao, Yoshitsugu Iinuma, et al.Science Signaling|February 7, 2019
Inhibition of T cell activation and function by the adaptor protein CIN85Mei Suen Kong, Akiko Hashimoto-Tane, Yusuke Kawashima, et al.International Journal of Hematology|April 25, 2020
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/dayYoshinori Hashimoto, Tomoki Ito, Yasuhiro Tanaka, et al.Pageof 10